Hematology Frontier

CAR-T cell therapy is rapidly advancing in the field of hematologic malignancies, including significant progress in the treatment of T-cell lymphomas. However, challenges such as relapse, off-target effects, and viral…

In the treatment of diffuse large B-cell lymphoma (DLBCL), the R-CHOP regimen has been a cornerstone, but enhancing its efficacy remains a significant challenge in the medical community. At the…

The 29th European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain, from June 13-16, 2024. As the largest international conference in the field of hematology in Europe,…

The 29th European Hematology Association (EHA) Annual Meeting took place from June 13-16, 2024, in Madrid, Spain. As Europe's largest international event in the field of hematology, the meeting attracts…

As we reflect on EHA 2024, the impact of this year’s congress continues to resonate within the hematology community. The groundbreaking research, innovative treatment strategies, and expert discussions presented at…

The recent European Hematology Association (EHA) Congress highlighted crucial advancements in hematology, emphasizing the significance of cutting-edge research and its impact on clinical practices. This year's sessions provided invaluable insights…

From clinical trials to real-world applications, the EHA Congress has bridged the gap between research and practice, enhancing the standard of care for hematological patients. #EHA2024 #BridgingTheGap

The European Hematology Association's 2024 Hybrid Congress is underway in Madrid, bringing together experts and professionals from around the world. From insightful sessions to groundbreaking research, this event is set…

Since 2015, the Chinese Society of Clinical Oncology (CSCO) has been dedicated to presenting annual reports on the progress of clinical oncology in China, under the theme "International Standards, Chinese Characteristics, Learning and Innovation." At the recent "2024 Annual Progress in Chinese Clinical Oncology Conference (BOC) and Best of ASCO 2024 China," the latest "Annual Advances in Chinese Clinical Oncology 2023" report was officially released. At this conference, Dr. Zhitao Ying from the Cancer Institute & Hospital Chinese Academy of Medical Sciences presented a detailed report on the advancements in lymphoma research in China for 2023.

The European Hematology Association (EHA) 2024 has concluded, leaving a trail of impactful insights and advancements in the field of hematology.Highlights included innovative therapies for blood cancers, breakthroughs in stem…